Preclinical enantioselective pharmacology of (R)- and (S)- ketorolac

Journal of Clinical Pharmacology

Volumn 38, Issue 2 SUPPL., 1998, Pages

  Handley, Dean A ^a   Cervoni, Peter ^b   McCray, John E ^a   McCullough, John R ^a  

^a SUNOVION PHARMACEUTICALS INC   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA OPIATE RECEPTOR; IBUPROFEN; KAPPA OPIATE RECEPTOR; KETOPROFEN; KETOROLAC; LIPOXYGENASE; MORPHINE SULFATE; MU OPIATE RECEPTOR; NORADRENALIN; OPIATE RECEPTOR; PROSTAGLANDIN SYNTHASE INHIBITOR; SEROTONIN RECEPTOR;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENANTIOMER; HUMAN; MALE; MOUSE; PAIN ASSESSMENT; RACEMIC MIXTURE; RAT; ULCEROGENESIS;

EID: 0031886250     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04414.x     Document Type: Article

References (34)

1. Jamali F, Mehvar R, Pasutto FM: Enantioselective aspects of drug action and disposition: Therapeutic pitfalls. J Pharm Sci 1989;78:695-715.
2. Jamali F: Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs. Eur J Drug Metab Pharmacokinet 1989;13:1-9.
3. Caldwell J, Hutt AJ, Fournel-Gigleux S: The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem Pharmacol 1988;37:105-114.
4. Yamaguchi T, Hirose K, Nakamura Y, Sugebo G: The inhibitory activities of 480156-S and its related compounds on prostaglandin synthase. Folia Pharmacol Jpn 1987;90:295-302.
5. Suesa N, Fernandez MF, Guiterrez M, Rufat MJ, Rotllan E, Calvo L, et al: Stereoselective cyclooxygenase inhibition in cellular models by the enantiomers of ketoprofen. Chirality 1993;5:589-595.
6. Ferrer X, Fernandez MF, Calvo L, et al: Anti-inflammatory activity of S-(+)-ketoprofen in the carrageenan-induced paw edema of the rat. Methods Find Exp Clin Pharmacol 1994;16(suppl 1):83-96.
7. Jerussi TP, Caubet JF, McCray JE, Handley DA: Clinical endoscopic evaluation of the gastroduodenal tolerance to (R)-ketoprofen, (R)-flurbiprofen, racemic ketoprofen and paracetamol: A randomized, single-blind, placebo-controlled trial. J Clin Pharmacol 1998;38(suppl):19S-24S.
8. Geisslinger G, Ferreira SH, Menzel S, Schlott D, Brune K: Antinociceptive actions of R(-)-flurbiprofen - a non-cyclooxygenase inhibiting 2 arylpropionic acid in rats. Life Sci 1994;54:PL173-177.
9. Wechter WJ: Epimerization in humans and clinical implications of the use of racemates. J Clin Pharmacol 1994;34:1036-1042.
10. Wechter WJ, Bigornia AE, Murray ED Jr, Levine BH, Young JW: Rac flurbiprofen is more ulcerogenic than its (S)-enantiomer. Chirality 1993;5:492-494.
11. Grossman CJ, Wiseman J, Lucas FS, Trevethick MA, Birch PJ: Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and COX-2 inhibitors. Inflam Res 1995;44:253-257.
12. Lotsch J, Geisslinger G, Mohammadian P, Brune K, Kobal G: Effects of flurbiprofen on pain-related chemosomatosensory-evoked potentials in human subjects. Br J Clin Pharmacol 1995;40:339-346.
13. Muchowski JM, Unger S, Ackrell J, Cheung P, Cook J, et al: Synthesis and anti-inflammatory and analgesic activity of 5-aroyl-1,2-dihydro-3H-pyrrolo[1,2a]pyrrole-1-carboxylic acids and related compounds. J Med Chem 1985;28:1037-1049.
14. Rooks WH, Maloney P, Shott L, Schuler M, Sevelius H, Strosberg A, et al: The analgesic and anti-inflammatory profile of ketorolac and its tromethamine salt. Drugs Exp Clin Res 1985;11:479-492.
15. Rooks WH, Tomolonis A, Maloney P, Wallack M, Schuler M: The analgesic and anti-inflammatory profile of (±)-5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2a]pyrrole-1-carboxylic acid (RS-37619). Agents Actions 1982;12:684-690.
16. Mroszczak E, Combs D, Chaplin M, Tsina I, Tarnowski T, Rocha A, et al: Chiral kinetics and dynamics of ketorolac. J Clin Pharmacol 1996;36:521-539.
17. McQuay HJ, Roppleton P, Carroll D, Summerfield RJ, Bullingham RES, Moore RE: Ketorolac and acetaminophen for orthopedic postoperative pain. Clin Pharmacol Ther 1986;39:89-94.
18. 3H]nisoxetine: A radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther 1992;260:427-436.
19. 3H]paroxetine binding in rat brain. J Neurochem 1988;50:1783-1790.
20. Yoburn BC, Lutfy K, Candido J: Species differences in μ-and δ-opioid receptors. Eur J Pharmacol 1991;193:105-108.
21. 5)enkephalin. Life Sci 1989;45:1001-1008.
22. 1-opioid receptor multiplicity in the guinea pig cerebellum. Eur J Pharmacol 1991;207:135-141.
23. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR: Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-11697.
24. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC: Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J Exp Med 1979;149:969-974.
25. Kargman S, Prasit P, Evans JF: Translocation of HL-60 cell 5-lipoxygenase. J Biol Chem 1991;266:23745-23752.
26. Tayeh MA, Marletta MA: Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. J Biol Chem 1989;264:19654-19658.
27. Pollock JS, Fostermann U, Mitchell JA, Warner TD, Schmidt HHH, Nakane M, et al: Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991;88:10480-10484.
28. Bredt DS, Snyder SH: Isolation of nitric oxide synthase, a calmodulin requiring enzyme. Proc Natl Acad Sci USA 1990; 87:682-685.
29. 50. In: Tallarida R, Murray R, eds. Pharmacologic calculations with computer programs. 2nd ed. New York: Springer-Verlag, 1987;153-159.
30. Lotsch J, Geisslinger G, Mahammadian P, Brune, Kobal G: Effects of flurbiprofen enantiomers on pain-related chemo-somatosensory evoked potentials in human subjects. Br J Clin Pharmacol 1995;40:339-346.
31. Limmroth V, Yu X, Moskowitz MA: R(-) but not the S(+)-ketoprofen attenuates neurogenic inflammation within the rat meninges. Pharmacologist 1997;39:81.
32. Wechter WJ, McCracker JD, Kantoci D, Murray ED, Quiggle D, Leipold D, et al: On the mechanism of the enhancement of intestinal ulcerogenicity of S-aryl proprionic acids by their R-enantiomers in the rat. [in press].
33. Daffonchio L, Rossoni G, Clavenna G, Omini C, Berti F: Protective activity of ketoprofen lysine salt against the pulmonary effects induced by bradykinin in guinea-pigs. Inflam Res 1995;45:259-264.
34. Evans AM: Pharmacodynamics and pharmacokinetics of the profens: Enantioselectivity, clinical implications, and special reference to (S+)-ibuprofen. J Clin Pharmacol 1996;36:7S-15S.